Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine
Launched by CHIRON CORPORATION · Dec 2, 2005
Trial Information
Current as of May 01, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy adolescents between and including 13-15 years of age, who provide written informed consent and who received one immunization with Chiron Meningococcal C Conjugate vaccine (Menjugate) during the UK immunization campaign and for which documentation can be provided.
- Exclusion Criteria:
- • Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease
About Chiron Corporation
Chiron Corporation, a pioneering biotechnology company, specializes in the development and commercialization of innovative therapeutic solutions and diagnostic products. With a strong focus on infectious diseases and cancer, Chiron leverages advanced research and development to address unmet medical needs. The company is committed to clinical excellence and adheres to the highest standards of regulatory compliance, ensuring that its trials are conducted with integrity and scientific rigor. Through collaboration with healthcare professionals and academic institutions, Chiron Corporation strives to enhance patient outcomes and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Patients applied
Trial Officials
Andrew J. Pollard, MBBS, FRCPCH, PhD
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials